Company: SION
Filing Date: 2025-11-05
Form Type: 10-Q
Source: 0001628280-25-049251
Chunk: 467

Company: Sionna Therapeutics, Inc.
Filing Date: 2025-11-05
Form: 10-Q
Item: Part I, Item 2
Chunk 467
---
 will continue to increase significantly, including the costs associated with operating as a public company. As a result, we will need additional capital to fund our operations, which we may obtain from additional equity or debt financings or strategic agreements.

As of September 30, 2025, we had $325.0 million in cash, cash equivalents and marketable securities.

Cash Flows

The following table sets forth a summary of the net cash flow activity (in thousands):

Nine Months Ended September 30,20252024Net cash used in operating activities$(49,671)$(41,006)Net cash used in investing activities(141,337)(142,141)Net cash provided by financing activities204,051 180,375 Net increase (decrease) in cash, cash equivalents and restricted cash$13,043 $(2,772)

Operating Activities

For the nine months ended September 30, 2025, net cash used in operating activities was $49.7 million primarily due to our net loss of $54.8 million and changes in operating assets and liabilities of $2.4 million, partially offset by $7.5 million of net non-cash charges, which includes stock-based compensation, depreciation, non-cash operating lease expense and amortization of discounts on marketable securities.

For the nine months ended September 30, 2024, net cash used in operating activities was $41.0 million  primarily due to our net loss of $45.8 million and changes in operating assets and liabilities of $6.2 million, partially offset by $11.0 million of net non-cash charges, which includes stock-based compensation, depreciation, non-cash operating lease expense, non-cash expense related to IPR&D acquisition and amortization of discounts on marketable securities.

Investing Activities

Net cash used in investing activities was $141.3 million during the nine months ended September 30, 2025, which was primarily driven by purchases of marketable securities of $282.1 million and purchases of property and equipment of $0.2 million, partially offset by maturities of marketable securities of $141.0 million.

23

Net cash used in investing activities was $142.1 million during the nine months ended September 30, 2024, due to purchases of marketable securities of $175.6 million, partially offset by maturities of marketable securities of $33.5 million.

Financing Activities

Net cash provided by financing activities was